https://seedless.graphicadevsite.com/kayothera-launches-with-seed-funding-round-from-njhf/2024-10-10T21:31:30+00:00https://seedless.graphicadevsite.com/kayothera-will-present-at-bionjs-10th-annual-biopartnering-conference/2024-10-10T21:32:11+00:00https://seedless.graphicadevsite.com/kayothera-founders-announce-discovery-of-a-new-organelle-driving-cancer-metastasis/2024-10-10T21:34:15+00:00https://seedless.graphicadevsite.com/kayothera-founders-publish-nature-cancer-review-on-new-therapeutic-strategies-to-treat-incurable-cancers/2024-10-10T21:28:41+00:00https://seedless.graphicadevsite.com/kayothera-to-graduate-from-endless-frontier-labs-accelerator/2024-10-10T21:28:03+00:00https://seedless.graphicadevsite.com/kayothera-selected-as-finalist-in-bios-start-up-stadium/2024-10-10T21:27:08+00:00https://seedless.graphicadevsite.com/bio-announces-kayothera-as-the-2021-start-up-stadium-winner/2024-10-10T21:24:55+00:00https://seedless.graphicadevsite.com/kayothera-selected-as-a-finalist-in-techuniteds-propelify-event/2024-10-10T21:24:03+00:00https://seedless.graphicadevsite.com/kayothera-inc-raises-8-million-in-series-a-financing-led-by-accelerator-life-science-partners-to-develop-novel-cancer-immunotherapeutics/2024-10-10T21:29:55+00:00https://seedless.graphicadevsite.com/kayothera-founder-presented-with-princeton-universitys-tiger-entrepreneur-award/2024-10-10T21:23:13+00:00https://seedless.graphicadevsite.com/expansion-to-type-2-diabetes/2024-10-10T21:21:35+00:00https://seedless.graphicadevsite.com/kayothera-inc-strengthens-financial-position-with-5-2-million-in-grant-and-expanded-series-a-funding-bringing-total-financial-support-to-14-million/2024-10-10T02:06:42+00:00https://seedless.graphicadevsite.com/washington-state-backs-ai-driven-cancer-diagnostics-and-other-startup-projects/2024-10-10T21:19:53+00:00https://seedless.graphicadevsite.com/kayothera-inc-nominates-first-in-class-oral-inhibitor-of-the-retinoid-pathway-in-genetically-defined-oncology-indications-as-a-development-candidate/2024-10-10T02:05:20+00:00https://seedless.graphicadevsite.com/lsinw-2024/2024-10-10T21:19:13+00:00https://seedless.graphicadevsite.com/bionj-biopartnering/2024-10-10T21:18:19+00:00https://seedless.graphicadevsite.com/wthe-pathogenic-role-of-retinoid-nuclear-receptor-signaling-in-cancer-and-metabolic-syndromes/2024-10-10T21:17:02+00:00https://seedless.graphicadevsite.com/kayothera-announces-new-appointments-to-board-of-directors/2024-10-14T05:06:31+00:00https://seedless.graphicadevsite.com/kayothera-announces-expansion-of-the-scientific-advisory-board/2024-10-21T17:22:07+00:00https://seedless.graphicadevsite.com/kayothera-named-as-a-winner-of-the-american-diabetes-associations-innovation-challenge-to-transform-type-2-diabetes-care/2025-09-04T16:26:16+00:00https://seedless.graphicadevsite.com/kayothera-inc-and-columbia-university-announce-publication-in-nature-communications-detailing-novel-therapeutic-strategy-for-type-2-diabetes/2025-09-04T16:32:46+00:00https://seedless.graphicadevsite.com/kayothera-inc-nominates-kayo-1732-a-first-in-class-oral-inhibitor-of-the-retinoid-nuclear-receptor-pathway-in-type-2-diabetes-and-cardiometabolic-indications-as-a-development-candidate/2025-09-22T22:36:26+00:00https://seedless.graphicadevsite.com/development-of-retinoid-nuclear-receptor-pathway-antagonists-through-targeting-aldehyde-dehydrogenase-1a3-aldh1a3/2025-10-14T03:37:37+00:00https://seedless.graphicadevsite.com/targeting-autocrine-retinoic-acid-signaling-by-aldh1a2-inhibition-enhances-antitumor-dendritic-cell-vaccine-efficacy/2026-01-05T17:23:56+00:00https://seedless.graphicadevsite.com/a-nuclear-target-to-revive-anti-tumor-immunity/2026-01-05T17:31:58+00:00https://seedless.graphicadevsite.com/kayothera-announces-expansion-of-clinical-advisory-board/2026-02-10T16:50:56+00:00